Veracyte/$VCYT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Ticker
$VCYT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
824
Website
Veracyte Metrics
BasicAdvanced
$2B
60.95
$0.41
2.07
-
Price and volume
Market cap
$2B
Beta
2.07
52-week high
$47.32
52-week low
$19.73
Average daily volume
1.1M
Financial strength
Current ratio
5.1
Quick ratio
4.541
Long term debt to equity
3.606
Total debt to equity
4.226
Interest coverage (TTM)
15,593.50%
Profitability
EBITDA (TTM)
54.418
Gross margin (TTM)
70.43%
Net profit margin (TTM)
7.13%
Operating margin (TTM)
8.43%
Effective tax rate (TTM)
5.79%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
1.55%
Return on equity (TTM)
2.86%
Valuation
Price to earnings (TTM)
60.948
Price to revenue (TTM)
4.212
Price to book
1.65
Price to tangible book (TTM)
5.77
Price to free cash flow (TTM)
24.88
Free cash flow yield (TTM)
4.02%
Free cash flow per share (TTM)
101.49%
Growth
Revenue change (TTM)
23.42%
Earnings per share change (TTM)
-144.54%
3-year revenue growth (CAGR)
22.74%
10-year revenue growth (CAGR)
27.16%
3-year earnings per share growth (CAGR)
-15.61%
10-year earnings per share growth (CAGR)
-11.33%
What the Analysts think about Veracyte
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Bulls say / Bears say
Veracyte reported a 21% increase in total revenue for Q4 2024, reaching $118.6 million, marking its 10th consecutive quarter of 20% or greater testing revenue growth. (Veracyte Press Release)
The Decipher Prostate test secured Level I evidence in the NCCN Clinical Practice Guidelines for Prostate Cancer, enhancing its credibility and potential market adoption. (Veracyte Press Release)
Veracyte expanded the availability of its Decipher Prostate test to patients with metastatic prostate cancer, potentially increasing its market reach. (Veracyte Press Release)
Veracyte is evaluating its operations in Marseille, France, and may cease funding its French subsidiary, which could lead to operational disruptions. (Veracyte Press Release)
The company reported a decrease in product revenue by 21% in Q3 2024 compared to the same period in 2023, indicating potential challenges in this segment. (Veracyte Press Release)
Veracyte's biopharmaceutical and other revenue decreased by 23% in Q3 2024 compared to Q3 2023, suggesting a decline in this revenue stream. (Veracyte Press Release)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Veracyte Financial Performance
Revenues and expenses
Veracyte Earnings Performance
Company profitability
Veracyte News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veracyte stock?
Veracyte (VCYT) has a market cap of $2B as of July 28, 2025.
What is the P/E ratio for Veracyte stock?
The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 60.95 as of July 28, 2025.
Does Veracyte stock pay dividends?
No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Veracyte dividend payment date?
Veracyte (VCYT) stock does not pay dividends to its shareholders.
What is the beta indicator for Veracyte?
Veracyte (VCYT) has a beta rating of 2.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.